ANI Pharma director granted 4,357 restricted shares

Pera Antonio R reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pera Antonio R reported acquisition or exercise transactions in this Form 4 filing.

ANI Pharmaceuticals director Antonio R. Pera received a grant of 4,357 shares of Common Stock as a restricted stock award. The award was granted at no cash cost to him and is part of his equity compensation.

The restricted shares are scheduled to vest in full on May 21, 2027, meaning they must be held until that date before becoming fully transferable. Following this grant, Pera directly holds a total of 27,017 shares of ANI Pharmaceuticals Common Stock.

Insider Trade Summary

Grant/Award: 4,357 shares

Grant/Award 1 txn

Insider Pera Antonio R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,357	$0.00	$0.00

Holdings After Transaction: Common Stock — 27,017 shares (Direct)

Footnotes (1)

F1. Represents a restricted stock award that will vest in full on May 21, 2027.

Key Figures

Restricted stock grant: 4,357 shares Grant price: $0.0000 per share Holdings after grant: 27,017 shares +1 more

4 metrics

Restricted stock grant 4,357 shares Restricted stock award to director Antonio R. Pera

Grant price $0.0000 per share Equity compensation, no cash paid by recipient

Holdings after grant 27,017 shares Total direct Common Stock held after transaction

Vesting date May 21, 2027 Restricted stock award vests in full on this date

Key Terms

restricted stock award, Common Stock, Form 4

3 terms

restricted stock award financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

Common Stock financial

"security_title: Common Stock reported as the type of shares granted."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) reporting the director’s equity grant."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANI Pharmaceuticals (ANIP) director Antonio R. Pera report on this Form 4?

Antonio R. Pera reported receiving 4,357 shares of ANI Pharmaceuticals Common Stock as a restricted stock award. The grant was a compensation-related equity award, not an open-market purchase, and increased his direct holdings to 27,017 shares after the transaction.

How many ANI Pharmaceuticals (ANIP) shares did Antonio R. Pera acquire in this transaction?

He acquired 4,357 shares of ANI Pharmaceuticals Common Stock through a restricted stock award. These shares were granted at no cash price per share and represent additional equity compensation, increasing his total direct holdings to 27,017 shares after the grant.

When do Antonio R. Pera’s restricted ANI Pharmaceuticals (ANIP) shares vest?

The restricted stock award will vest in full on May 21, 2027. Until that vesting date, the 4,357 shares remain subject to vesting conditions, after which they become fully owned and transferable as ordinary Common Stock, assuming those conditions are met.

What is Antonio R. Pera’s total ANI Pharmaceuticals (ANIP) ownership after this award?

After the restricted stock award, Antonio R. Pera directly holds 27,017 shares of ANI Pharmaceuticals Common Stock. This total includes the newly granted 4,357 restricted shares, which are scheduled to vest in full on May 21, 2027, subject to applicable conditions.

Was cash paid for the ANI Pharmaceuticals (ANIP) shares reported on this Form 4?

No cash was paid for these shares; the transaction price per share is listed as 0.0000. The 4,357 shares were issued as a restricted stock award, reflecting equity-based compensation rather than an open-market purchase by Antonio R. Pera.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/10/2026 - 09:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pera Antonio R

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		A⁽¹⁾		4,357	A	$0	27,017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a restricted stock award that will vest in full on May 21, 2027.

Remarks:

	/s/ Antonio R. Pera, by attorney-in-fact Meredith W. Cook	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR